Navigation Links
Possible treatment target found for main cause of severe liver disease in kids
Date:11/8/2011

CINCINNATI -- Unexpected discovery of a new molecular signature for a destructive and often lethal pediatric liver disease may lead to a new therapeutic target for the hard-to-treat condition.

In a study that included human livers and a mouse model of biliary atresia, researchers report in the November Journal of Clinical Investigation that not all children with biliary atresia share the same disease process. Some patients have a second molecular conductor of disease called Th2 (T helper cell 2) immune system.

Biliary atresia is disease that destroys the bile ducts in and near the liver in the first few months of life. Driven by an overly aggressive immune system response after birth, the condition is the most common cause of severe pediatric liver disease. The ducts, which normally carry bile from the liver and gall bladder to the intestines, become blocked over time. Even with treatment, which can include surgery, children often need a liver transplant within two years of birth.

Despite the need for better therapies, progress has been hampered by a limited knowledge of biological processes driving the disease, according to Jorge Bezerra, MD, principal study investigator and a researcher/physician in the division of Gastroenterology, Hepatology and Nutrition at Cincinnati Children's Hospital Medical Center.

"Our findings add a new dimension to the understanding of biliary atresia," Bezerra said. "They provide a potential target for new therapies and have implications for clinical trials. Now, depending on the molecular signature of a child's disease, we can develop new strategies to also target the Th2 immune system with anti-inflammatory agents."

Bezerra said physicians have learned in clinical trials that not all children with biliary atresia respond in similar fashion to the same treatment protocols. The current study may help explain why.

Until now, only molecular signals from the Th1 cytokines
'/>"/>

Contact: Nick Miller
nicholas.miller@cchmc.org
513-803-6035
Cincinnati Children's Hospital Medical Center
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Link possible between pet food contamination and baby formula contamination
2. Inherited genetic cause, possible treatment found for complex lung disorder
3. Argonne scientists discover possible mechanism for creating handedness in biological molecules
4. Vitamin E shows possible promise in easing chronic inflammation
5. Nanotechnology culture war possible, says Yale study
6. Rice University study finds possible clues to epilepsy, autism
7. Pitt, NETL researchers report molecular chain reaction thought to be impossible
8. MU researcher identifies possible genetic causes of borderline personality disorder
9. Our unconscious brain makes the best decisions possible
10. Promising new drug being evaluated as possible treatment option for fragile X syndrome
11. Control of blood vessels a possible weapon against obesity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2015)... June 23, 2015  Crossmatch™, a leading ... today announced enhanced functionality of its DigitalPersona ... The enhancements build on the native flexibility ... Altus platform and provide expanded mobile credential ... In today,s environment of increasing cyber-attacks and ...
(Date:6/17/2015)... , and HILDEN, Germany , June 17, ... ; Frankfurt Prime Standard: QIA) today launched new Investigator ® ... forensic laboratories in the United States . ... simultaneously analyze multiple key genomic markers (short tandem repeats or ... Quality Sensor to evaluate the quality of DNA in each ...
(Date:6/16/2015)...  With the increasing number and severity of data ... The recent compromise of Federal employee data from ... within government agencies. HYPR Corp. announced today ... authenticator, has been submitted for testing and approval of ... for tamper proofing. The proliferation of ...
Breaking Biology News(10 mins):Crossmatch Releases Enhanced DigitalPersona Altus Advanced Authentication Functionality 2QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 2QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 3QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 4QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 5Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 2Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 3
... Cruz Mountains two closely related species of mice share a ... lives. The California mouse ( Peromyscus californicus ) is characterized ... maniculatus ) is sexually promiscuous. Researchers at the University ... behavior impact the bacteria hosted by each species as well ...
... trials can be time-consuming, expensive and intrusive, but they ... Space Institute in Tullahoma have developed an invention that ... the virtual world. Called "digital Eye Bank," the ... eyes for researchers to use when testing their inventions. ...
... federal research effort to evaluate freshwater sustainability across the ... can be done to make the best use of ... the effects of climate change over the next 10 ... of Georgia are also part of the project. ...
Cached Biology News:Monogamy and the immune system 2Monogamy and the immune system 3Monogamy and the immune system 4Monogamy and the immune system 5University of Tennessee Space Institute researchers make clinical trials a virtual reality 2NC State leads national effort to evaluate fresh water sustainability in the southern US 2
(Date:6/30/2015)... ... 2015 , ... The maximum number of shares proposed to be purchased in ... of unvested restricted stock). On June 29, 2015, the last trading day prior to ... on the OTCBB was $2.29 per share. , The tender offer will expire on ...
(Date:6/30/2015)... HAUPPAUGE, N.Y. , June 30, 2015  Custom ... provider, announced today that they are silver sponsors of ... an official PCDC sponsor, Custom is lending their support ... in low-income communities. Since its founding in ... for the primary care area.  PCDC has financed over ...
(Date:6/30/2015)... ... June 30, 2015 , ... ... has accepted the position of vice president of instruction at Chippewa Valley Technical ... “I greatly appreciated the opportunity to lead SIUE during the past three years,” ...
(Date:6/29/2015)... Brooklyn, NY (PRWEB) , ... June 30, 2015 , ... ... Shimadzu and Perkin Elmer machines. Featuring 12 distinct peaks, the WAV-8 is the ... a machine is in spec deep into the NIR range. Previous spectrophotometer calibration standards, ...
Breaking Biology Technology:Cryo-Cell Commences Tender Offer to Purchase its Common Stock, Up to 750,000 Shares at $3.25 per Share 2Cryo-Cell Commences Tender Offer to Purchase its Common Stock, Up to 750,000 Shares at $3.25 per Share 3Custom Computer Specialists Announces Sponsorship Of The Primary Care Development Corporation's Corporate Circle 2SIUE’s Furst-Bowe Accepts VP of Instruction at CVTC 2SIUE’s Furst-Bowe Accepts VP of Instruction at CVTC 3FireflySci Releases Spectrophotometer Calibration Standards for NIR Wavelength Accuracy Verification 2FireflySci Releases Spectrophotometer Calibration Standards for NIR Wavelength Accuracy Verification 3
... Biovista Inc. today,announced that BVA-101, its drug targeting ... the MOG-induced Experimental Allergic,Encephalomyelitis (EAE) murine model of ... MS and is aimed at neuroprotection, was shown ... toxic effects in this well,established model of MS. ...
... announced that Merck & Co. Inc. has chosen ... collaboration agreement announced in June 2008 to apply ... novel small molecule leads against several drug targets.By ... a new multi-million member proprietary library of small ...
... manager of Xmark Opportunity Fund, L.P. and Xmark Opportunity Fund, Ltd., sent the following letter to the Board of Directors of Icagen, Inc. ... XMARK OPPORTUNITY PARTNERS, LLC, ... 90 Grove Street, ... 201, ...
Cached Biology Technology:Biovista Inc. Announces Positive Efficacy Results in a Pre-Clinical Trial of its BVA-101 Repositioned Drug for Multiple Sclerosis 2Nuevolution Announces Progress in Its Collaboration With Merck & Co. Inc. 2Xmark Requests That Icagen Oust Its CEO and Pursue Strategic Alternatives, and Calls on Board Members to Resign 2
Mouse monoclonal [3F8 ] to smooth muscle Myosin heavy chain I ( Abpromise for all tested applications). entrezGeneID: 4629 SwissProtID: P35749...
Rabbit polyclonal to pCrosstide (HRP) ( Abpromise for all tested applications)....
IkappaB-alpha (112B2) Mouse mAb...
Human sIL-2R/CD25 ELI-PAIR Kit...
Biology Products: